Kaitlyn D’Onofrio

DocwireNews

A case report and literature review examined the effect of teriflunomide in patients with multiple sclerosis (MS) who develop COVID-19.The subject of the case report was a 57-year-old male with MS who was treated with teriflunomide and developed a mild case of COVID-19. The literature review consisted of the five papers published since February 2020 discussing 14 patients with MS who contracted COVID-19 while on teriflunomide treatment. The cohort had an average age of 50.5 &plusmn; 11.3 years, and 53% of patients were female. The median Expanded Disability Status Scale (EDSS) score was 2.25 (range, 0-6), and patients had been on teriflunomide treatment for an average 3.7 &plusmn; 1.6 years. Four patients had relevant comorbidities. All patients with COVID-19 had a fever; the other most common symptoms were gastrointestinal disturbances (67%), fatigue (55%), and cough (55%). Five patients went to the hospital, and two needed oxygen support.When evaluating the entire study cohort and comparing the patients who required hospitalization (n=5) versus those who did not (n=10), the hospitalized group was significantly older (59.6 years vs. 45.9 years; P=0.025), but there were no significant differences in sex, EDSS, duration of teriflunomide therapy, and comorbidities. All patients had good outcomes. Recovery time varied from a few days to several weeks. All but two patients continued their teriflunomide treatment regimen during the course of their COVID-19 infection.The man from the case report had a short duration of teriflunomide therapy by about 2.5 years compared with that of the literature review group and had a median EDSS score 1.5 points lower. He required hospitalization and had significant comorbidities but did not require oxygen support, did not need intensive care, and returned home after 10 days, so he was considered to have good outcomes. He remained on teriflunomide therapy during the course of his disease.&ldquo;Available data suggest that teriflunomide therapy should not be discontinued in [patients with] MS who develop SARS-CoV-2 infection, also in presence of significant comorbidities or clinical conditions requiring hospitalization,&rdquo; the study authors concluded. &ldquo;Additional studies are necessary to assess if the drug can also have a protective role against SARS-CoV-2.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Teriflunomide in Patients with MS and COVID-19

Multiple Sclerosis

A case report and literature review examined the effect of teriflunomide in patients with multiple sclerosis (MS) who develop COVID-19. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe